Literature DB >> 6825749

Transtracheal aspiration in pulmonary infection in children with cystic fibrosis.

I Brook, R Fink.   

Abstract

Six transtracheal aspirations (TTA) and expectorated sputum specimens were collected from four children suffering from cystic fibrosis who had pulmonary infection. Specimens obtained from both sites were cultured for aerobic bacteria and TTA aspirates were also cultured for anaerobes. Differences in bacteria isolated in TTA and sputum aspirates were present in all instances. Six isolates were recovered in both sites (three Pseudomonas aeruginosa, two Staphylococcus aureus and one Aspergillus flavus). Five aerobic isolates were recovered only in the expectorated sputum and not in TTA aspirations (two Klebsiella pneumoniae and one each of P. aeruginosa, Escherichia coli and Proteus mirabilis). Nine organisms were isolated only from the TTA (two each of Veillonella parvula and Alpha hemolytic streptococci, and one each of Bacteroides fragilis, B. melaninogenicus, Lactobacillus sp., Haemophilus influenzae and Gamma hemolytic streptococci). The recovery of anaerobic organisms from four of the six TTA specimens suggests a possible role for these organisms in the etiology of pulmonary infection in cystic fibrosis. We found TTA to be helpful in the bacterial diagnosis and management of pulmonary infections in cystic fibrosis.

Entities:  

Mesh:

Year:  1983        PMID: 6825749

Source DB:  PubMed          Journal:  Eur J Respir Dis        ISSN: 0106-4339


  8 in total

Review 1.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

2.  Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods.

Authors:  Edith T Zemanick; Brandie D Wagner; Charles E Robertson; Mark J Stevens; Stanley J Szefler; Frank J Accurso; Scott D Sagel; J Kirk Harris
Journal:  Ann Am Thorac Soc       Date:  2015-02

Review 3.  Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi.

Authors:  James F Chmiel; Timothy R Aksamit; Sanjay H Chotirmall; Elliott C Dasenbrook; J Stuart Elborn; John J LiPuma; Sarath C Ranganathan; Valerie J Waters; Felix A Ratjen
Journal:  Ann Am Thorac Soc       Date:  2014-10

4.  Use of denaturing high-performance liquid chromatography (DHPLC) to characterize the bacterial and fungal airway microbiota of cystic fibrosis patients.

Authors:  Jérôme Mounier; Audrey Gouëllo; Marlène Keravec; Solène Le Gal; Grégory Pacini; Stella Debaets; Gilles Nevez; Gilles Rault; Georges Barbier; Geneviève Héry-Arnaud
Journal:  J Microbiol       Date:  2014-02-17       Impact factor: 3.422

5.  The upper respiratory tract as a microbial source for pulmonary infections in cystic fibrosis. Parallels from island biogeography.

Authors:  Katrine L Whiteson; Barbara Bailey; Megan Bergkessel; Douglas Conrad; Laurence Delhaes; Ben Felts; J Kirk Harris; Ryan Hunter; Yan Wei Lim; Heather Maughan; Robert Quinn; Peter Salamon; James Sullivan; Brandie D Wagner; Paul B Rainey
Journal:  Am J Respir Crit Care Med       Date:  2014-06-01       Impact factor: 21.405

6.  Bacterial activity in cystic fibrosis lung infections.

Authors:  Geraint B Rogers; Mary P Carroll; David J Serisier; Peter M Hockey; Valia Kehagia; Graeme R Jones; Kenneth D Bruce
Journal:  Respir Res       Date:  2005-06-01

7.  Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis.

Authors:  Ohad Manor; Roie Levy; Christopher E Pope; Hillary S Hayden; Mitchell J Brittnacher; Rogan Carr; Matthew C Radey; Kyle R Hager; Sonya L Heltshe; Bonnie W Ramsey; Samuel I Miller; Lucas R Hoffman; Elhanan Borenstein
Journal:  Sci Rep       Date:  2016-03-04       Impact factor: 4.379

8.  Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis.

Authors:  Shaun Nielsen; Bronwen Needham; Steven T Leach; Andrew S Day; Adam Jaffe; Torsten Thomas; Chee Y Ooi
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.